Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception

NCT06727734 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 980

Last updated 2026-05-14

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the failure rate of the levonorgestrel (LNG)-piroxicam combination regimen versus ulipristal acetate (UPA) as emergency contraception (EC). The main questions it aims to answer are:

1. whether the LNG-piroxicam combination regimen has a lower failure rate than UPA for EC;
2. whether the LNG-piroxicam combination regimen has a higher percentage of pregnancies prevented than UPA for EC
3. whether there is any difference in the change in the subsequent menstrual cycle and adverse effect profile between the two regimens

Participants will:

1. Take a single dose of either (i) LNG 1.5 mg plus piroxicam 40 mg and a placebo tablet resembling UPA, or (ii) UPA 30 mg plus placebo tablets resembling LNG and piroxicam.
2. Have a blood test for serum LH, oestradiol an progesterone.
3. Keep a diary of their vaginal bleeding episodes, adverse effects symptoms, any further acts of intercourse and the type of contraception used.
4. Have a follow-up either in person by phone about 1-2 weeks after the next expected menstruation.
5. If normal menstrual bleeding has not occurred by that time, a pregnancy test will be carried out.

Conditions

  • Contraception

Interventions

DRUG

Levonorgestrel

Levonorgestrel 1.5 mg

DRUG

Piroxicam

Piroxicam 40 mg

DRUG

Ulipristal Acetate

Ulipristal 30 mg

DRUG

Placebo - LNG

Placebo of levonorgestrel

DRUG

Placebo - Piroxicam

Placebo of piroxicam

DRUG

Placebo - UPA

Placebo of ulipristal acetate

Sponsors & Collaborators

  • The Family Planning Association of Hong Kong

    collaborator OTHER
  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Raymond Hang Wun Li, MD, FRCOG · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-18
Primary Completion
2027-09-30
Completion
2027-10-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06727734 on ClinicalTrials.gov